Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Immix Biopharma Inc

Healthcare US IMMX

7.93USD
-0.49(5.82%)

Last update at 2026-06-05T20:00:00Z

Day Range

7.768.37
LowHigh

52 Week Range

1.557.75
LowHigh

Fundamentals

  • Previous Close 8.42
  • Market Cap61.02M
  • Volume1257805
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.13565M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.95

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -8.21945M -24.37787M -1.13032M -0.95226M
Minority interest - - - -
Net income -8.22971M -24.38388M -1.14786M -0.97281M
Selling general administrative 4.02M 1.23M 0.21M 0.26M
Selling and marketing expenses - - - -
Gross profit -89.51700M - - -
Reconciled depreciation 0.00214M 0.00247M 0.00232M 0.00108M
Ebit -8.21895M -1.35201M -0.45385M -0.84250M
Ebitda -8.21681M -1.34955M -0.45102M -0.84119M
Depreciation and amortization 0.00214M 0.00247M 0.00283M 0.00131M
Non operating income net other - - - -
Operating income -8.21895M -1.35201M -0.45385M -0.84250M
Other operating expenses 8.22M 1.35M 0.45M 0.84M
Interest expense 0.00050M 0.18M 0.10M 0.11M
Tax provision 0.01M 0.00601M 0.02M 0.02M
Interest income - - - -
Net interest income -0.00050M -0.17985M -0.10198M -0.10998M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.01M 0.00601M 0.02M 0.02M
Total revenue -89.51700M 0.00000M 0.00000M 0.00000M
Total operating expenses 8.22M 1.35M 0.45M 0.84M
Cost of revenue - - - -
Total other income expense net -0.00050M -23.02585M -0.67646M -0.10976M
Discontinued operations - - - -
Net income from continuing ops -8.22971M -24.38388M -1.14786M -0.97281M
Net income applicable to common shares -8.22971M -24.38388M -1.14786M -0.97281M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 19.93M 14.91M 18.19M 0.54M 0.94M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.11M 1.21M 0.52M 0.01M 0.02M
Total liab 3.72M 1.75M 0.20M 5.27M 4.59M
Total stockholder equity 16.41M 13.16M 17.99M -4.73058M -3.64636M
Deferred long term liab - - - - -
Other current liab 2.29M - 0.00910M 0.57M 0.24M
Common stock 0.00200M 0.00140M 0.00132M 0.00034M 0.00034M
Capital stock 0.00200M 0.00140M 0.00132M 0.00034M 0.00034M
Retained earnings -53.41130M -37.98525M -29.75553M -5.37165M -4.22379M
Other liab - 0.47M - - -
Good will - - - - -
Other assets - 0.00672M - - -
Cash 17.51M 13.44M 17.64M 0.39M 0.73M
Cash and equivalents - - - - -
Total current liabilities 3.72M 1.27M 0.20M 5.27M 4.59M
Current deferred revenue - - - 0.34M -
Net debt -17.50979M -13.43671M -17.59448M 3.71M 3.37M
Short term debt - - 0.05M 4.10M 4.10M
Short long term debt - - 0.05M 4.10M 4.10M
Short long term debt total - - 0.05M 4.10M 4.10M
Other stockholder equity 69.68M 51.06M 47.62M 0.51M 0.51M
Property plant equipment - 0.00356M 0.00570M 0.00736M 0.00968M
Total current assets 19.79M 14.90M 18.19M 0.53M 0.93M
Long term investments - - - - -
Net tangible assets - 13.16M 17.99M -4.73058M -3.64636M
Short term investments - - - - -
Net receivables 1.17M 0.26M 0.03M 0.13M 0.18M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.43M 1.27M 0.14M 0.25M 0.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.13M 0.09M 0.13M 0.13M 0.07M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.09M 0.00672M 0.00570M - -
Deferred long term asset charges - - - - -
Non current assets total 0.14M 0.01M 0.00570M 0.00736M 0.00968M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.00000M -0.00080M 0.00000M -0.00731M
Change to liabilities 1.13M -0.10606M -0.00383M 0.12M
Total cashflows from investing activities - -0.00080M -0.00080M -0.00731M
Net borrowings -0.05000M 0.20M 0.20M 1.05M
Total cash from financing activities 3.23M 18.85M 18.85M 1.05M
Change to operating activities -0.70015M -0.38264M 0.11M 0.10M
Net income -8.22971M -24.38388M -1.14786M -0.97281M
Change in cash -4.20776M 17.25M -0.34293M 0.27M
Begin period cash flow 17.64M 0.39M 0.73M 0.46M
End period cash flow 13.44M 17.64M 0.39M 0.73M
Total cash from operating activities -7.40830M -1.58931M -0.40469M -0.79003M
Issuance of capital stock 2.91M 18.65M - -
Depreciation 0.00214M 0.00247M 0.00232M 0.00108M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock -0.09996M - - -
Other cashflows from financing activities 0.47M 0.20M 0.47M -0.00731M
Change to netincome 0.62M 23.12M 0.57M 0.57M
Capital expenditures 0.00000M 0.00080M 0.00080M 0.00731M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.20M -0.39104M 0.17M 0.18M
Stock based compensation 0.52M 0.22M - -
Other non cash items 0.10M 0.12M 0.58M 0.00108M
Free cash flow -7.40830M -1.59011M -0.40469M -0.79734M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
IMMX
Immix Biopharma Inc		 -0.49 5.82% 7.93 - - - 4.47 -3.4935
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma Inc

11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064

Key Executives

Name Title Year Born
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. Co-Founder, Chairman & CEO 1973
Mr. Gabriel Morris B.A. CFO & Director 1987
Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc Co-Founder NA
Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. Scientific Co-Founder 1947
Mr. Ben H. Lyon J.D. Exec. VP & Gen. Counsel NA
Dr. Graham Ross FFPM, M.D. Acting Chief Medical Officer & Head of Clinical Devel. 1960
Mr. Nandan Oza B.S. Head of Chemistry, Manufacturing & Control 1962
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. Co-Founder, CEO & Chairman 1973
Mr. Ben H. Lyon J.D. Executive VP & General Counsel NA
Dr. Graham Ross FFPM, M.D. Chief Medical Officer & Head of Clinical Development 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions